[Retracted] Antileukemic Effects of Anti-miR-146a, Anti-miR-155, Anti-miR-181a, and Prednisolone on Childhood Acute Lymphoblastic Leukemia

Table 3

Effects of anti-miR and prednisolone treatment on the viability of SUP-B15 and NCI-BL 2171 cells.

Treatment group	Viability compared to control (%)
	SUP-B15	NCI-BL 2171
Anti-miR-146a	29.62	57.36
Anti-miR-146a & IC50 dose of prednisolone	2.44	52.32
Anti-miR-155	55.00	52.09
Anti-miR-155 & IC50 dose of prednisolone	13.75	43.30
Anti-miR-181a	13.03	58.18
Anti-miR-181a & IC50 dose of prednisolone	9.17	46.91
Anti-let-7e	9.17	49.82
Anti-let-7e & IC50 dose of prednisolone	3.14	49.52
Anti-miR-146a + anti-miR-155 + anti-miR-181a + anti-let-7e combination	13.75	41.10
Anti-miR-146a + anti-miR-155 + anti-miR-181a + anti-let-7e combination & IC50 dose of prednisolone	0.00	52.22
IC50 dose of prednisolone	41.25	56.91

Fisher’s exact test, <0.05, <0.001, and <0.0001.